Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Development of Machine Learning Systems to Predict Cancer-Related Symptoms With Validation Across a Health Care System
1
Zitationen
23
Autoren
2025
Jahr
Abstract
PURPOSE Cancer and its treatment cause symptoms. In this study, we aimed to develop machine learning (ML) systems that predict future symptom deterioration among people receiving treatment for cancer and then validate the systems in a simulated deployment across an entire health care system. METHODS We trained and tested ML systems that predict a deterioration in nine patient-reported symptoms within 30 days after treatments for aerodigestive cancers, using internal electronic health record (EHR) data at Princess Margaret Cancer Centre (3,229 patients; 20,267 treatments). The primary performance metric was the area under the receiver operating characteristic curve (AUROC). The best-performing systems in the held-out internal test set were then externally validated across 82 cancer centers in Ontario (12,079 patients; 77,003 treatments) by adapting techniques from meta-analysis. RESULTS The best ML systems predicted symptom deterioration with AUROCs ranging from 0.66 (95% CI, 0.63 to 0.69) for dyspnea to 0.73 (95% CI, 0.71 to 0.75) for drowsiness in the internal test cohort. Treatments flagged as high-risk were significantly associated with future symptom deterioration (odds ratios [ORs], 2.53-6.56; all P < .001) and emergency department visits for dyspnea (OR, 1.85; P = .008), depression (OR, 1.84; P = .04), and anxiety (OR, 2.66; P < .001). In the external validation cohort, the AUROCs for different symptoms meta-analyzed across centers ranged from 0.67 (95% CI, 0.66 to 0.68) to 0.73 (95% CI, 0.72 to 0.74). Performance across centers displayed significant heterogeneity for six of nine symptoms (I 2 , 46.4%-66.9%; P = .004 for dyspnea, P < .001 for the rest). CONCLUSION ML can predict future symptoms among people with cancer from routine EHR data, which could guide personalized interventions. Heterogeneous performance across centers must be considered when systems are deployed across a health care system.
Ähnliche Arbeiten
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.866 Zit.
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 · 7.376 Zit.
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
1993 · 6.006 Zit.
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008
2010 · 5.054 Zit.
Interpretation of Changes in Health-related Quality of Life
2003 · 4.572 Zit.